Quick Takeaways:
- Zoetis has launched Lenivia (izenivetmab) in Canada and the EU, introducing a long-acting monoclonal antibody for canine osteoarthritis pain. A single subcutaneous injection provides up to three months of pain relief, with clinical benefits observed as early as Day 7 in a pivotal nine-month study.
- Lenivia targets nerve growth factor (NGF), a key mediator of pain and inflammation, and binds to a different NGF site than existing anti-NGF therapies. The launch addresses growing demand for convenient, long-term OA pain management as more dogs live longer and osteoarthritis becomes increasingly prevalent.
- Lenivia expands Zoetis’ canine OA portfolio alongside Rimadyl, Trocoxil, and Librela. The company said the therapy offers sustained pain control, improved treatment compliance, and greater convenience for pet owners while providing veterinarians with another option for long-term osteoarthritis management.
Why It Matters?
Zoetis’s launch of Lenivia (izenivetmab) in Canada and the EU introduces the first long-acting monoclonal antibody for canine osteoarthritis that binds a different NGF site than existing anti‑NGF therapies, offering up to three months of pain relief from a single injection and becoming another high-margin, non-oral option in a rapidly growing veterinary pain market. By diversifying the OA portfolio alongside NSAIDs (Rimadyl, Trocoxil) and a cat-compatible anti-NGF (Librela), Lenivia is likely to shift treatment patterns toward injectable, long-interval therapies, strengthen Zoetis’s position in veterinary pain, and increase stickiness of its product ecosystem through quarterly dosing and improved compliance.
Source: Businesswire
